Ripretinib
Qinlock · KIT switch-control inhibitor
Hypertension and alopecia in GIST.
Aliqopa · COP
Pan-PI3K inhibitor · approved 2017 · 6 citations
Describes how this page is sourced, not how dangerous the drug is. Thinly sourced means fewer of the sourcing signals are met — not that the agent is kidney-safe. A rule-based summary, not a formal certainty appraisal.
IV pan-PI3K inhibitor with reproducible transient infusion-related hypertension and hyperglycemia — a vascular/metabolic signature rather than a structural nephropathy.
Atlas fields gathered in one place, each linked to the section with its full text and sources. Educational, not medical advice.
Signature lesion
On monotherapy (CHRONOS-1), transient on-infusion-day hypertension occurs in 29.6% all-grade (grade 3 23.9%), and hyperglycemia in 50.0% all-grade (grade 3 33.1%, grade 4 7.0%); with rituximab (CHRONOS-3) the grade 3-4 rates are higher — hypertension 40% and hyperglycemia 56%. Both peak within hours of the infusion and largely resolve by the next day. Sustained renal injury is uncommon.Source: Dreyling et al., Am J Hematol 2020 (CHRONOS-1; 50.0% all-grade transient hyperglycemia, grade 3 33.1% — an on-target metabolic effect, not renal injury); Matasar et al., Lancet Oncol 2021 (CHRONOS-3; grade 3-4 hyperglycemia 56%, hypertension 40%)
Infusion-bound — within hours of each dose, resolving within ~24 h.
Distilled from: “Acute and infusion-bound — within hours of each dose, resolving within ~24 h.”
This agent's defining kidney lesion — its #1 signature. Cited incidence is shown where a citable figure exists; otherwise the tier stands qualitatively.
Raised blood pressure — archetypally on-target loss of endothelial nitric oxide from VEGF-pathway blockade, studied as a pharmacodynamic marker of drug exposure. Other agents raise it too: vascular effects of BCR-ABL, BTK and RET inhibitors and of copanlisib; abiraterone's mineralocorticoid excess; androgen suppression or blockade.
Intravenous pan-class-I PI3K inhibitor with predominant activity against the alpha and delta isoforms. Intermittent IV dosing blocks PI3K/AKT signaling in follicular and other indolent B-cell lymphomas.
Vasculature / Endothelium
Glomerular & peritubular capillaries
6 primary references — trials, cohorts, mechanism, and reviews. Citation metadata via PubMed / NLM.
Primary (non–case-report) references per year — a proxy for how actively the agent's renal literature is accruing. Recent years are highlighted. Reflects curation depth, not a systematic bibliometric count.
Everything below is FAERS — adverse events someone chose to report, about 403 of them for this agent. Nobody counts the patients who were fine, so none of these numbers is an incidence, a risk, or a rate: they describe what gets reported, shaped by a drug's fame, its indication, and who was watching. How these numbers work.
Only significant signals appear (95% CI lower bound above 1) — a phenotype missing here was tested and did not reach significance, except Prerenal / Hemodynamic AKI, Pseudo-AKI, Renal Cysts, Chronic Interstitial Nephropathy — outside the clinician-reviewed MedDRA term map, never queried — and ATN and AIN, queried but biopsy-bound: real cases are filed as generic “acute kidney injury”, so their absence is not a negative. As of 2026-11-15.
What reporting says about this profile's documented lesions
Reported with a death outcome
49 of 403 reports
Reported with hospitalization
237 of 403 reports
Reports per year
Reports received per year, 2015–2026 · most recent year is partial.
Bars rank systems by summed reaction-term mentions (a report counts once per term it names) — an ordinal “more vs less reported” cue, not a tally of distinct reports. Renal & urinary first. As of 2026-11-15.
Each recommendation below is this atlas's faithful summary of the source, not a quotation from it — follow the PubMed link for the wording the society published. Summaries may be superseded; consult the current full text and individualize to the patient.
General onco-nephrology references
Where Copanlisib sits in nephrotoxicity space — each dot is an anti-cancer agent, positioned so neighbors share a kidney-injury phenotype. Its 6 closest are filled and lead to a numbered marker, matching the numbered cards below.
Qinlock · KIT switch-control inhibitor
Hypertension and alopecia in GIST.
Lupron · GnRH agonist
Metabolic syndrome; indirect renal risk.
Scemblix · BCR-ABL STAMP inhibitor
Hypertension and pancreatitis; allosteric BCR-ABL inhibitor.
Xtandi · Androgen-receptor inhibitor
Hypertension; rare electrolyte effects.
Unituxin · Anti-GD2 antibody
Capillary-leak syndrome, hypertension and severe pain in neuroblastoma.
Iclusig · BCR-ABL TKI
Vascular toxicity and hypertension.
Nearest agents by kidney-injury phenotype (shared injuries, nephron target, severity, class) — a similarity approximation, not a claim of shared drug identity or mechanism.
Same-class agents ordered by their documented kidney-injury profile — atlas severity, an acute-kidney-injury FAERS signal, and how many injury types each is documented to cause. Agents nearer the top carry the lighter documented renal profile. Agents sharing a number are tied on all three. An agent marked FAERS n/a has too few reports to test, so its place rests on severity and injury breadth alone.
A comparison of documented kidney-injury data within one drug class — not a substitution recommendation. Efficacy, indication, and non-renal toxicity differ between these agents and are out of scope here. Educational only, not medical advice.